Gabapentin for pain management following major surgery: a placebo controlled, double blind, randomized clinical trial (The GAP Study).
Baos S. et al, (2025), Anesthesiology
Stereotactic radiotherapy for nAMD: areas for improvement - Authors' reply.
Jackson TL. et al, (2025), Lancet, 406, 26 - 27
Distributional cost-effectiveness analysis in genomic medicine: Considerations for addressing health equity.
Smith HS. et al, (2025), Value Health
Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework.
Smith HS. et al, (2025), Appl Health Econ Health Policy, 23, 337 - 358
Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumor DNA: A Comparative Microcosting Study.
Morrell L. et al, (2025), Value Health Reg Issues, 48
Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial.
By-Band-Sleeve Collaborative Group None., (2025), Lancet Diabetes Endocrinol
Using liquid biopsy in early lung cancer diagnosis: a systematic review of health economic analyses and budget impact analysis for the UK NHS
Kew E. et al, (2025), Journal of Thoracic Oncology, 20
How, why and when are delayed (back-up) antibiotic prescriptions used in primary care? A realist review integrating concepts of uncertainty in healthcare.
Mcleod M. et al, (2024), BMC Public Health, 24
Using orthopaedic health care resources efficiently: A cost analysis of day surgery for unicompartmental knee replacement.
Hlatshwako TG. et al, (2024), Knee, 49, 147 - 157
Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases in England and Canada.
Weymann D. et al, (2024), JAMA Netw Open, 7
Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use.
Roope LSJ. et al, (2024), Commun Med (Lond), 4
Population screening requires robust evidence-genomics is no exception.
Turnbull C. et al, (2023), Lancet
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.
Kovács G. et al, (2023), Per Med
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
Nagy B. et al, (2023), Per Med
Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries.
Szilberhorn L. et al, (2023), Per Med
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
Koleva-Kolarova R. et al, (2023), Per Med